target directory

castration resistant prostate cancer clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT00933426

Source recordAI-normalized

A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases

This clinical trial aimed to evaluate the safety and efficacy of lenalidomide in combination with paclitaxel for men with castration-resistant prostate cancer. The study was conducted by M.D. Anderson Cancer Center and sponsored by Celgene Corporation. It was terminated early due to slow patient accrual.

AI analysis

Indication: Prostate Cancer

Modality: small molecule

Target: Castration-Resistant Prostate Cancer

Sponsor: M.D. Anderson Cancer Center

Source URL: ClinicalTrials.gov

Source updated: Oct 26, 2016

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Castration-Resistant Prostate Cancer

View original source fields

Condition raw: Prostate Cancer

Condition normalized: Prostate Cancer

Modality raw: Prostate Cancer

Modality normalized: small molecule

Target raw: Castration-Resistant Prostate Cancer

Target normalized: Castration-Resistant Prostate Cancer

Open report

NCT03869762

Source recordAI-normalized

A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

The DICE trial investigated the combination of Denosumab and Enzalutamide in patients with progressive metastatic castration-resistant prostate cancer and bone metastases. The study was terminated due to insufficient patient accrual, with only 7 participants enrolled.

AI analysis

Indication: Castration-resistant Prostate Cancer

Modality: monoclonal antibody

Target: Castration-resistant Prostate Cancer

Sponsor: Cancer Trials Ireland

Source URL: ClinicalTrials.gov

Source updated: Apr 13, 2026

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Castration-resistant Prostate Cancer

View original source fields

Condition raw: Castration-resistant Prostate Cancer

Condition normalized: Castration-resistant Prostate Cancer